Prospects for therapy of HIV-associated neurologic diseases

References

• Acker M B. Relationships between test scores and everyday life functioning. Clinical Neuropsychology of Intervention, B P Uzzell, Y Gross. Martinus Nijhoff Publishing, Boston 1986; 85–117
   Google Scholar
• Ad Hoc FDA Dementia Assessment Task Force. Antidementia Drug Assessment Symposium. Neurobiology of Aging 1991; 12: 379–382
   Google Scholar
• Adamson D C, Wildemann B, Sasaki M, Glass J D, McArthur J C, Christov V I, Dawson T M, Dawson V L. Immunologic nitric oxide synthase: Elevation in severe AIDS dementia and induction by HIV‐1 coat protein, gp41. Science 1996; 274: 1917–1921
   PubMed Web of Science ®Google Scholar
• Albert S M, Marder K, Dooneief G, Bell K, Sano M, Todak G, Stern Y. Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Arch Neurol 1995a; 52: 525–530
   PubMed Web of Science ®Google Scholar
• Albert S M, Todak G, Elkin E, Marder K, Dooneief G, Stern Y. Time allocation and disability in HIV infection: A correlational study. J Occup Sci 1995b; 1: 21–30
   Google Scholar
• Bacellar H, Munoz A, Miller E N, Cohen B A, Besley D, Seines O A, Becker J T, McArthur J C. Temporal trends in the incidence of HIV‐1 related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology 1994; 44: 1892–1900
   PubMed Web of Science ®Google Scholar
• Barker P B, Lee R R, McArthur J C. AIDS dementia complex: Evaluation with proton MR spectroscopic imaging. Radiology 1995; 195: 58–64
   Google Scholar
• Belman A L, Diamond G, Dickson D, Horoupian D, Llena J, Lantos G, Rubinstein A. Pediatric acquired immunodeficiency syndrome. Neurologic syndromes ‘published erratum appears in Am J Dis Child 1988 May; 142(5):507’. Am J Dis Child 1988; 142: 29–35
   PubMedGoogle Scholar
• Benos D J, Hahn B H, Bubien J K, Ghosh S K, Mashbum N A, Chaikin M A, Shaw G M, Benveniste E N. Envelope glycoprotein gp120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: Implications for AIDS dementia complex. Proc Natl Acad Sci USA 1994; 91: 494–498
   Google Scholar
• Bouwman F H, Skolasky R, Hes D, Seines O A, Glass J D, Nance‐Sproson T E, Royal W, Dal Pan G J, McArthur J C. Rapid progression of HIV‐associated dementia: Association with CNS immune activation. 1996, (Un Pub)
   Google Scholar
• Burger D M, Kraayeveld C L, Meenhorst P L, Mulder J W, Hoetelmans R M W, Koks C H W, Beijnen J H. Study on didanosine concentrations in cerebrospinal fluid. Pharmacy World & Science 1995; 17: 218–221
   PubMedGoogle Scholar
• Butler K M, Husson R N, Balis R M, Brouwers P, Eddy J, el‐Amin D, Gress J, Hawkins M, Jarosinki P, Moss H, Poplack D, Santacroce S, Venzon D, Wiener L, Wolters P, Pizzo P A. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 324: 137–144
   PubMed Web of Science ®Google Scholar
• Chiesi A, Vella S, Dally L G, Pedersen C, Danner S, Johnson A M, Schwander S, Goebel F D, Glauser M, Antunes F, Lundgren J D. Epidemiology of AIDS dementia complex in Europe. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996; 11: 39–44
   PubMed Web of Science ®Google Scholar
• Cinque P, Vago L, Brytting M, Castagna A, Accordini A, Sundqvist V ‐A, Zanchetta N, D'Arminio Monforte A, Wahren B, Lazzarin A, Linde A. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis 1992; 166: 1408–1411
   PubMed Web of Science ®Google Scholar
• Cinque P, Vago L, Dahl H, Brytting M, Terreni M R, Fornara C, Racca S, Castagna A, Monforte A D, Wahren B, Lazzarin A, Linde A. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus‐associated opportunistic diseases of the central nervous system in HIV‐infected patients. AIDS 1996; 10: 951–958
   PubMed Web of Science ®Google Scholar
• Cohen B A, McArthur J C, Grohman S, Patterson B, Glass J D. Neurologic prognosis in CMV polyradiculomyelopathy in AIDS. Neurology 1993; 43: 493–499
   Google Scholar
• Cohen R A, O'Donnell B F, Meadows M E, Moonis M, Stone W F, Drachman D A. ERP indicies and neuropsychological performance as predictors of functional outcome in dementia. Journal of Geriatric Psychiatry & Neurology 1995; 8: 217–225
   Google Scholar
• Dana Consortium for Treatment of HIV Dementia. Anti‐oxidant treatment in HIV dementia. Neuroscience of HIV Infection March 6–9, 1996, Paris
   Google Scholar
• Davis K L, Thai L J, Gamzu E R, Davis C S, Woolson R F, Gracon S I, Drachman D A, Schneider L S, Whitehouse P J, Hoover T M, Morris J C, Kawas C H, Knopman D S, Earl N L, Kumar V, Doody RS and The Tacrine Collaborative Study Group. A double‐blind, placebo‐controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253–1259
   PubMed Web of Science ®Google Scholar
• Dewhurst S, Gelbard H A, Fine S M. Neuropathogenesis of AIDS (review). Molecular Medicine Today 1996; 2: 16–23
   Google Scholar
• Dieterich D T, Poles M A, Lew E A, Mendez P A, Murphy R, Addessi A, Holbrook J T, Naughton K, Friedberg D N. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993; 167: 1184–1188
   PubMedGoogle Scholar
• Fein G, Biggins C A, Mackay S. Delayed latency of the event‐related brain potential P3A component in HIV disease. Progressive effects with increasing cognitive impairment. Arch Neurol 1995; 52: 1109–1118
   PubMedGoogle Scholar
• Fillet A M, Katlama C, Visse B, Camilleri S, Rogeaux O, Huraux J M. Human CMV infection of the CNS: concordance between PCR detection in CSF and pathological examination. AIDS 1993; 7: 1016–1017
   Google Scholar
• Gallant J E, Moore R D, Richman D D, Keruly J, Chaisson R E, Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992; 166: 1223–1227
   PubMed Web of Science ®Google Scholar
• Gelbard H A, Dzenko K A, DiLoreto D, del Cerro C, del Cerro M, Epstein L G. Neurotoxic effects of tumor necrosis factor alpha in primary human neuronal cultures are mediated by activation of the glutamate AMPA receptor subtype: Implications for AIDS neuropathogenesis. Dev Neurosci 1993; 15: 417–422
   PubMed Web of Science ®Google Scholar
• Gelbard H A, Nottet H S L M, Swindells S, Jett M, Dzenko K A, Genis P, White R, Wang L, Choi Y B, Zhang D X, Lipton S A, Tourtellotte W W, Epstein L G, Gendelman H E. Platelet activating factor. A candidate human immunodeficiency virus type 1‐induced neurotoxin. J Virol 1994; 68: 4628–4635
   PubMed Web of Science ®Google Scholar
• Glass J D, Fedor H, Wesselingh S L, McArthur J C. Immunocytochemical quantitation of HIV in the brain: Correlations with HIV‐associated dementia. Ann Neurol 1995; 38: 755–762
   PubMed Web of Science ®Google Scholar
• Gozlan J, Salord J M, Roullet E, Baudrimont M, Caburet F, Meyohas M C, Duvivier C, Jacomet C, Petit J C. Rapid detection of cytomegalovirus DNA in cerebrospinal fluid of AIDS patients with neurologic disorders. J Infect Dis 1992; 166: 1416–1421
   PubMedGoogle Scholar
• Gozlan J, El Amrani M, Baudrimont M, Costagliola D, Salord J M, Duvivier C, Picard O, Meyohas M, Jacomet C, Schneider‐Fauveau V, Petit J ‐C, Roullet E. A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus‐related neurological diseases during AIDS. AIDS 1995; 9: 253–260
   PubMed Web of Science ®Google Scholar
• Graham N M H, Hoover D R, Park L P, Stein D S, Phair J P, Mellors J W, Detels R, Saah A J, Taylor E, Margolick J B, Markham R, McArthur J, Farzadegan H, Armenian H, Chmeil J S, Cohen B, Wesch J, Wolinsky S, Visscher B R, Fahey J L, Giorgi J V, Dudley J, Lee M, Nishanian P, Rinaldo C R. Survival in HIV‐infected patients who have received zidovudine. Comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996; 124: 1031–1038
   PubMed Web of Science ®Google Scholar
• Griffin D E, Wesselingh S L, McArthur J C. Elevated central nervous system prostaglandins in HIV‐associated dementia. Ann Neurol 1994; 35: 592–597
   PubMed Web of Science ®Google Scholar
• Heaton R K, Chelune G J, Lehman R A. Using neuropsychological and personality tests to assess the likelihood of patient employment. J Nerv Ment Dis 1978; 166: 408–416
   PubMed Web of Science ®Google Scholar
• Heaton R K, Velin R A, McCutchan J A, Gulevich S J, Atkinson J H, Wallace M R, Godfrey H P D, Kirson D A, Grant I, The HNRC Group. Neuropsychological impairment in human immunodeficiency virus‐infection: Implications for employment. Psychosomatic Med 1994; 56: 8–17
   PubMed Web of Science ®Google Scholar
• Hill R D, Backman L, Fratiglioni L. Determinants of functional abilities in dementia. J Am Geriatrics Soc 1995; 43: 1092–1097
   PubMed Web of Science ®Google Scholar
• Huang S, Skolasky R, Dal Pan G J, Royal W, McArthur J C. Survival prolongation and sympton palliation in HIV seropositive patients with PML treated with alpha interferon. 1996, (Un Pub)
   Google Scholar
• Janssen R S, Nwanyanwu O C, Selik R M, Stehr‐Green J K. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992; 42: 1472–1476
   PubMed Web of Science ®Google Scholar
• Kerr D A, Chang C F, Gordon J, Bjornsti M A, Khalili K. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 1993; 196: 612–618
   PubMed Web of Science ®Google Scholar
• Koka P, Zack J A, Kitchen S, Peacock W, Fried I, Tran Y, Yashar S S, Merrill J E. Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. J Exp Med 1995; 182: 941–951
   PubMed Web of Science ®Google Scholar
• Lipton S A, Gendelman H E. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995; 332: 934–940
   PubMed Web of Science ®Google Scholar
• Magnuson D S K, Knudsen B E, Geiger J D, Brownstone R M, Nath A. Human immunodeficiency virus type 1 Tat activates non‐N‐methyl‐D‐aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 1995; 37: 373–380
   PubMed Web of Science ®Google Scholar
• Maj M, Satz P, Janssen R, Zaudig M, Starace F, D'Elia L, Sughondhabirom B, Mussa M, Naber D, Ndetei D, Schulte G, Sartorius N. WHO Neuropsychiatry AIDS Study, Cross‐sectional Phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry 1994; 51: 51–61
   PubMed Web of Science ®Google Scholar
• Manischewitz J F, Quinnan G V, Lane H C, Wittek A E. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990; 34: 373–375
   PubMed Web of Science ®Google Scholar
• McArthur J C, Seines O A, Dal Gan G J, Yost B, Oette D, Gelpke L, Clifford D, Price R W, Wesselingh S, Griffin D E. Phase I/II trial of pentoxifylline in HIV‐associated dementia and myelopathy. Neuroscience of HIV Infection: Basic and Clinical Frontiers Vancouver BC. Aug 2–5, 1994
   Google Scholar
• McArthur J C, Grant I. HIV neurocognitive disorders. Neurological and Neuropsychiatric Manifestations of HIV‐1 Infection. 1996, (In Press)
   Google Scholar
• McConnell J R, Swindells S, Ong C S, Gmeiner W H, Chu W K, Brown D K, Gendelman H E. Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment. AIDS Res Hum Retroviruses 1994; 10: 977–982
   Google Scholar
• McKinney R E, Jr, Maha M A, Connor E M, Feinberg J, Scott G B, Wulfsohn M, McIntosh K, Borkowsky W, Modlin J F, Weintrub P, O'Donnell K, Gelber R D, Knowlton Rogers G, Nusinoff Lehrman S, Wilfert C M, Protocol 043 Study Group. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991; 324: 1018–1025
   PubMed Web of Science ®Google Scholar
• Moore R D, Chaisson R E. Natural history of opportunistic disease in an HIV‐infected urban clinical cohort. Ann Intern Med 1996; 124: 633
   PubMed Web of Science ®Google Scholar
• Navia B A, Dafni U, Simpson D, Slasor P, McArthur J, Zaborski L, Lipton S A. A Phase I/II trial of nimodipine for the treatment of neurological manifestations associated with HIV infection, including AIDS dementia complex and peripheral neuropathy. 1996, (Un Pub)
   Google Scholar
• Nordic Medical Research Councils HIV Therapy Group. Double blind dose‐response study of zidovudine in AIDS and advanced HIV infection. Br Med J 1992; 304: 13–17
   Google Scholar
• Persidsky Y, Limoges J, McComb R, Bock P, Baldwin T, Tyor W, Patil A, Nottet H S L., Epstein L, Gelbard H, Flanagan E, Reinhard J, Pirruccello S J, Howard E, Gendelman H E. Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol 1996; 149: 1027–1053
   Google Scholar
• Philippon V, Vellutini C, Gambarelli D, Harkiss G, Arbuthnott G, Metzger D, Roubin R, Filippi P. The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: Involvement of cytokines. Virology 1994; 205: 519–529
   PubMed Web of Science ®Google Scholar
• Pizzo P A, Eddy J, Falloon J, Balis F M, Murphy R F, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988; 319: 889–896
   PubMed Web of Science ®Google Scholar
• Portegies P, de Gans J, Lange J M, Derix M M, Speelman H, Bakker M, Danner S A, Goudsmit J. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment ‘published erratum appears in BMJ 1989 Nov 4;299(6708):1141’. Br Med J 1989; 299: 819–821
   PubMed Web of Science ®Google Scholar
• Rao S M, Leo G J, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991; 41: 692–696
   PubMed Web of Science ®Google Scholar
• Rothlind J C, Bylsma F W, Peyser C, Folstein S E, Brandt J. Cognitive and motor correlates of everyday functioning in early Huntington's disease. J Nerv Ment Dis 1993; 181: 194–199
   PubMed Web of Science ®Google Scholar
• Sardar A M, Bell J E, Reynolds G P. Increased concentrations of the neurotoxin 3‐hydroxykynurenine in the frontal cortex of HIV‐1 ‐positive patients. J Neurochem 1995; 64: 932–935
   PubMedGoogle Scholar
• Sidtis J J, Gatsonis C, Price R W, Singer E J, Collier A C, Richman D D, Hirsch M S, Schaerf F W, Fischl M A, Kieburtz K, Simpson D, Koch M A, Feinberg J, Dafni R, AIDS Clinical Trials Group. Zidovudine treatment of the AIDS dementia complex: results of a placebo‐controlled trial. Ann Neurol 1993; 33: 343–349
   PubMed Web of Science ®Google Scholar
• Sidtis J J. Evaluation of the AIDS dementia complex in adults. HIV, AIDS and the Brain, R W Price, S W Perry. Raven Press, New York 1994; 273–287
   Google Scholar
• Talley A K, Dewhurst S, Perry S, Dollard S C, Gummuluru S, Fine S M, New D, Epstein L G, Gendelman H E, Gelbard H A. Tumor necrosis factor alpha induces apoptosis in human neuronal cells: Protection by the antioxidant N‐acetylcysteine and the genes bcl‐2 and crm A. Mol Cell Biol 1995; 15: 2359–2366
   Google Scholar
• The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Clinical confirmation of the American Academy of Neurology algorithm for HIV‐1 associated cognitive/motor disorder. Neurology 1996; 47: 1247–1253
   Google Scholar
• Toggas S M, Masliah E, Rockenstein E M, Rail G F, Abraham C R, Mucke L. Central nervous system damage produced by expression of the HIV‐1 coat protein gp120 in transgenic mice. Nature 1994; 367: 188–193
   PubMed Web of Science ®Google Scholar
• Tozzi V, Narciso P, Galgani S, Sette P, Balestra P, Gerace C, Pau F M, Pigorini F, Volpini V, Camporiondo M P. Effects of zidovudine in 30 patients with mild to end‐stage AIDS dementia complex. AIDS 1993; 7: 683–692
   Web of Science ®Google Scholar
• Tross S, Price R W, Navia B, Thaler H T, Gold J, Sidtis J J. Neuropsychololgical characterization of the AIDS dementia complex: a preliminary report. AIDS 1988; 2: 81–88
   PubMed Web of Science ®Google Scholar
• Van Gorp W G, Hinkin C, Satz P, Miller E N, Weisman J, Holston S, Drebing C, Marcotte T D, Dixon W. Subtypes of HIV‐related neuropsychological functioning: a cluster analysis approach. Neuropsychology 1993; 7: 62–72
   Google Scholar
• Volterra A, Trotti D, Racagni G. Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms. Mol Phar 1994; 46: 986–992
   PubMed Web of Science ®Google Scholar
• Weinberg D V, Murphy R, Naughton K. Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. Am J Ophthalmol 1994; 117: 776–782
   PubMedGoogle Scholar
• Weinshenker B G, Issa M, Baskerville J. Metaanalysis of the placebo‐treated groups in clinical trials of progressive MS. Neurology 1996; 46: 1613–1619
   Google Scholar
• Wesselingh S L, Power C, Glass J, Tyor W R, McArthur J C, Farber J M, Griffin J W, Griffin D E. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993; 33: 576–582
   PubMedGoogle Scholar
• Wolf D G, Spector S A. Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J Infect Dis 1992; 166: 1412–1415
   PubMed Web of Science ®Google Scholar
• Yeung M C, Pulliam L, Lau A S. The HIV envelope protein gp120 is toxic to human brain‐cell cultures through the induction of interleukin‐6 and tumor necrosis factor‐a. AIDS 1995; 9: 137–143
   PubMed Web of Science ®Google Scholar